Anavex Life Sciences Corporation News - AVXL

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex...

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia...

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Anavex Life Sciences Provides an Update on Rett Syndrome Program

Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation...

Steady_T 3 minutes ago

OK. You win. $400 a share it is. 😉

👍️0

nidan7500 12 minutes ago

A buyout would be fine...@ $100/sh. Steady T

A buy out would be fine ...@$400/ish /share

🎯 1 👍️ 1

georgejjl 15 minutes ago

DrJan:

What do you think about Anavex 3-71 for the treatment of schizophrenia?

https://www.anavex.com/post/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schi

BMS paid Karuna at least $12 billion for Kar XT

Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety

ANAVEX®3-71’s differentiated dual novel mechanism of action offers the potential to synergistically activate both SIGMAR1 and M1 muscarinic receptors and treat all symptom domains of schizophrenia without the side effects of standard of care antipsychotics

Anavex 3-71 was formerly referred to as AF710b and was invented in Israel by Dr. Abraham Fisher PhD.

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1323

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1303

https://pubmed.ncbi.nlm.nih.gov/29291374/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803577/

Good luck and GOD bless,

👍️0

Steady_T 55 minutes ago

7 months isn't up yet.

👍️0

Reyeton 56 minutes ago

Maybe they could use that test on the “super responders” from years ago to better prove they had Alzheimer Disease.

💩 1 🦨 1

k9uwa 1 hour ago

If the Company gets off their collective butts and gets the EMA filed then someone might be interested.
John k9uwa

👎️ 1

BIOChecker4 1 hour ago

You’ve been saying the same thing for at least 156 fort nights. If any of these companies were actually interested in partnering with or buying Anavex, they’d have done it by now.

Therefore, I am absolutely certain that Roche is not interested in partnering with or buying Anavex Life Sciences or licensing Blarcamesine from Anavex, nor do I believe that JNJ, Merck, Eli Lilly and Pfizer among other big Pharma are interested in Anavex Life Sciences.

👎️ 1 💩 1

k9uwa 1 hour ago

I'll Second that one!!!
John k9uwa

"A buyout would be fine...@ $100/sh"

👍️0

mike_dotcom 2 hours ago

I've stopped fantasizing.

👍️ 1

Steady_T 2 hours ago

A buyout would be fine...@ $100/sh.

👍️ 3

k9uwa 2 hours ago

And as soon as a patient gets a Positive Test for ALZ. That patient should be on Anavex 2-73.
John k9uwa

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease from other neurodegenerative disorders.

👍️ 3

mike_dotcom 2 hours ago

Please, somebody buy this POS company.

👎️ 1 💩 3

georgejjl 2 hours ago

I am absolutely certain that Roche is interested in partnering with or buying Anavex Life Sciences or licensing Blarcamesine from Anavex.

I have believe that JNJ, Merck, Eli Lilly and Pfizer among other big Pharma are also interested in Anavex Life Sciences.

Good luck and GOD bless,

👍️0

meds4life 2 hours ago

Is this the same plasma tau protein which Anavex tested for in the 2b-3 AD study?

👍️0

georgejjl 2 hours ago

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease from other neurodegenerative disorders.

The test, developed by Roche in collaboration with Eli Lilly, is intended to support a more accurate Alzheimer’s diagnosis in adults, ages 60 and older, when used with other clinical assessments.

https://alzheimersnewstoday.com/news/biomarker-test-diagnose-alzheimers-wins-fda-breakthrough-designation/?utm_source=ALZ&utm_campaign=0b36ef3530-Email_ENL__US_ALZ&utm_medium=email&utm_term=0_94425accb7-0b36ef3530-73402633

Good luck and GOD bless,

👍️0

BIOChecker4 3 hours ago

Thanks for the clarification.

👍️ 2 👎️ 1 💩 1

k9uwa 3 hours ago

Not difficult to understand Biochecker. No I wouldn't mind if Missling were replaced with someone with experience at bringing new drugs to market. I do think the science is sound. For sure we are SAFE which is a lot more than most other drugs. The only other thing I would be interesting in hearing him say would be. We are partnering with Merck.

👍️0

nidan7500 3 hours ago

Our competition is having an uphill grind with the medical community!

https://www.fiercepharma.com/marketing/leqembi-launch-hamstrung-physicians-therapeutic-nihilism

STAND UP....HOOK UP.....MOVE TO THE DOOR....JUMP....HAPPY LANDINGS

👍️ 1

LakeshoreLeo1953 3 hours ago

The stock will go up considerably (trading ranges don't count)
only when the science is proven.
It may well go up more rapidly let alone more period if and when
your CEO scenario is in place.
I'd settle for the science and then bitch about the leadership as much
as I am a doubting Thomas for each.

👎️ 1 💩 1

BIOChecker4 3 hours ago

Your gibberish is hard to parse but I’ll say again that you defend Missling at your financial peril. I don’t understand the loyalty to a guy who has train-wrecked shareholder value, except that losing money is somehow preferable to admitting being wrong.

The stock will go up if Missling is replaced by a credible CEO with a track record of success. Missling is neither indispensable nor irreplaceable. These things happen. Why is that so difficult to accept?

👍️ 2 👎️ 1 💩 1

k9uwa 3 hours ago

"It’s astounding and deeply concerning, though of course the WGTers will dismiss these things as unimportant."

NOT TRUE. What I would like to hear are these words. Good Morning Chris Missling for Anavex. We are in process of filing EMA. Now I would like to turn the mic
over to Barwicki or one of the others QUALIFIED to SPEAK not in "Heir Engrish". As to the Q/A when a question comes in whoever is best QUALIFIED to answer should speak up... but not Chris. Yes, since 2015 I have made a killing from Anavex Stock. I am sure that we do have the drug to solve AZ and other CNS issues. Chris at least has us NOT IN DEBT but it is time for those who know the answers to SPEAK.

John k9uwa

👍️ 1

Talon38 3 hours ago

Our competition is having an uphill grind with the medical community!

https://www.fiercepharma.com/marketing/leqembi-launch-hamstrung-physicians-therapeutic-nihilism

👍️ 3

BIOChecker4 3 hours ago

He’s still here to protect people from you.

👍️ 1 👎️ 1 💩 1

BIOChecker4 3 hours ago

Even so, Missling’s dismal performance is inexcusable. He uses buzzwords to distract retail and to give retail something to get excited about. Sadly, it seems to work with many.

👍️ 1 👎️ 1 💩 1

ignatiusrielly35 4 hours ago

Wow. Just … wow. Your linear thinking and comprehension is a sight to behold.

👍️ 2 👎️ 1 💩 1 🤣 1

georgejjl 4 hours ago

Ignatiousreilly53,

Why are you still posting here if you sold out this morning?

GOD bless,

🤡 2

JoeBear906 4 hours ago

I worked 10 years at one german firm and 2 years at another.

👍️ 1

Steady_T 4 hours ago

Toutain had been with the company since 2018.

Looks like he left for a significant increase in pay.PDS Biotechnology Corporation has appointed Stephan F. Toutain as their new Chief Operations Officer, starting May 1, 2024. Bringing over three decades of pharmaceutical industry experience, Toutain has held significant roles at companies like Anavex Life Sciences and Interleukin Genetics. His compensation includes a $450,000 annual salary with potential for a 40% bonus, stock options, and severance benefits under certain conditions. The company announced his appointment in a press release on May 2, 2024.

👍️ 1

ExtremelyBullishZig 4 hours ago

No one is going to pay 600M for this POS.Large placebo effect...

🐀 1 👎️ 1 👺 1 💩 1 ☹️ 1

ExtremelyBullishZig 4 hours ago

Sure it is. Unfortunately, no would pay that much for it.

ignatiusrielly35 5 hours ago

Personally, I didn’t find Dr. Jan’s comments to be grossly negative or overblown.

👍️ 4 👎️ 1 💩 1

sumbuysumsell 5 hours ago

The IT term is GIGO.

💩 1 🤡 1

Graniteguy 5 hours ago

Exactly bas2020! I’m “DrGraniteGuy” and approve your message.
So many in the know “Pharmaceutical Master Minds” inhabit this board doling out doses of misinformation…my time value spent here has diminished dramatically.

🎯 1 🏆️ 1 👍️ 5

kund 5 hours ago

One more addition to your list, hope you keep clown ceo busy investigating FUDsters rather than running and completing trials.

🐀 1 👍️ 1 👎️ 1 👺 1 💩 1

BIOChecker4 5 hours ago

There is no poster on this board except maybe Xena who is more steeped in conspiracy theories or a bigger apologist for our incompetent CEO than you. You and your investment group (if it ever existed) must have lost six or even seven figures buying this stock on every dip from $30 down.

I fail to see why you defend Missling to the death (or financial ruin) when all he’s accomplished is to make himself wealthy at shareholders’ expense. Missling is neither essential nor irreplaceable. The announcement of a new CEO with a solid track record of success and the respect of institutional biotech investors would have an immediate, positive impact on the stock price.

I guess some people just prefer to lose money than have to admit to being wrong about the guy.

🐀 1 👍️ 1 👎️ 1 👺 1 💩 2 🦨 1

BIOChecker4 5 hours ago

It boggles my mind that the CEO of a biotech company either doesn’t understand or doesn’t care about the importance clear, concise communications with investors and other stakeholders . The WGTers here will of course excuse this dereliction of duty by saying that the only thing that matters is results, which of course is utter nonsense.

Even if there are nefarious players on Wall Street looking to take AVXL down, what Missling is doing only enables them. It’s like opening the hen-house door and inviting the fox in for lunch.

What’s clear over the course of his tenure is that Missling has learned NOTHING. The guy has cost shareholders a great deal of money and his compliant board of directors has allowed it to go on and on.

The sooner this guy is gone, the better. He is hardly essential or irreplaceable.

🎯 1 🏆️ 1 🐀 1 👍️ 2 👎️ 1 👺 1 💩 1

bas2020 5 hours ago

Welcome to the board, "Dr". So nice to have another expert FUDster show up after the recent SP manipulation. So, whose FUD seat did you take over on this board? OFP, DRexpact, Anshu2, growingpain, Inquirig, or someone else?

🎯 1 👍️ 10 💩 1 🤡 1

frrol 5 hours ago

Prospects for AD looking up. Rett is pushed back. I6f like to see Missing accompanied by our new Research head on future clinical calls and presentations, but prospects for that are low. His poor credibility is a bit of a problem. Not a fan of his endpoint spinning and cherry picking, nor other investors.

I'm looking forward to our MAA getting submitted, and outcome of our FDA interactions. The AD climate has improved in our favor.

🐀 1 👎️ 1 👺 1 💩 1

DrJan 6 hours ago

Go to their website, e.g. under 'news' the most recent thing is from 2022, as well under the quick link 'presentations'. His presentations are also full of redundancies and lack focus. He just doesn't realize how important the right communication is and nobody will tell him.

🎯 1 🏆️ 1 🐀 2 👍️ 2 👎️ 1 👺 4 💩 3

kund 6 hours ago

WGT will love this X from AF
------------------------------------------------------------
$PDSB just hired a new COO who came from $AVXL.

Oh boy...

🐀 1 👺 1 💩 1 🖕 1

BIOChecker4 6 hours ago

It’s laziness and/or lack of interest on Missling’s part. The company description should be updated regularly. It should also be shortened. Why does he even mention pain and various types of cancer? It’s absurd and not credible. If Missling is too lazy to notice these things, why don’t Clint Tomlinson and especially Andrew Barwicki do something about it? That’s what they’re paid well to do.

When Missling can’t even be bothered to update the company description in its PRs or the website, it really makes me wonder how he’s going to get any regulatory filings right.

It’s astounding and deeply concerning, though of course the WGTers will dismiss these things as unimportant.

🎯 1 🏆️ 1 🐀 1 👍️ 2 👎️ 1 👺 1 💩 1

Investor2014 6 hours ago

I could see that happen much sooner.
could see OTC in 5 years
Assuming you mean the $AVXL stock.

🐀 1 👍️ 1 👺 2 💩 2 🤡 2

Investor2014 6 hours ago

Georgejjl seems to have fetish for finding those that go south.
This is beginning to look like a 10 cent penny stock.
While pumping them all the way there.

🐀 1 👍️ 1 👺 1 💩 1 🤡 2

Reyeton 6 hours ago

And her unrelenting negative emoji’s seem to be her frugal attempt at censorship.

🐀 1 👍️ 2 👺 1

Jonjones325 6 hours ago

I put COO leaving in the Super Duper AI Fantastical Speculator Machine and it said - Anavex will partner with a large pharma and one of their executives will come in to be the COO.

One can dream!

🆖 1 👍️ 2 💩 1 😀 1

Investor2014 6 hours ago

My guess is that your many and deeply insightful posts here played a big part in attracting another actual Dr. to this message board.

🐀 1 👍️ 1 👎️ 1 👺 2 💩 2 🤡 1

longtermbeliever 6 hours ago

different people handle different scale of the company.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

🆖 1 👍️ 2 💩 1

longtermbeliever 7 hours ago

COO leaving the company does not mean is bad.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

🆖 1 👍️ 2 💩 1

kund 7 hours ago

COO gone, he got tired of playing ping-pong with invisible Misleading. Ultimately people get tired of too much of free time/vacation and they will leave for other opportunity, unlike Misleading, who is always in Europe, vacationing with model. Next week CC he will conduct it from his bed.

🐀 1 👍️ 1 👎️ 1 👺 1 💩 1

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL)

Get an advanced news scanner tailored to your needs by ADVFN

AVXL News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences Provides an Update on Rett Syndrome Program

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL) News

Anavex Life Sciences Corporation (AVXL)

Get an advanced news scanner tailored to your needs by ADVFN

AVXL News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences Provides an Update on Rett Syndrome Program

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App